The top medtech stories of early 2017

March 27, 2017 By Chris Newmarker

[Image courtesy of Insulet]

Diabetes treatment advances

There was also positive news on the diabetes device front.

Insulet said the 1st feasibility study of its Omnipod Horizon hybrid closed-loop system showed the automated glucose control algorithm performed well, with minimal hypoglycemia, and that it was safe for use by people with type 1 diabetes. Production is expected to start at a new Acton, Mass. plant in 2019.

DexCom meanwhile announced that CMS has classified therapeutic continuous glucose monitors as durable medical equipment under Medicare Part B. The company said the Dexcom G5 Mobile is the only continuous glucose monitor to that falls under the classification, with the Medicare coverage giving DexCom a potential competitive advantage.

Pages: 1 2 3 4 5 6

About The Author

Chris Newmarker

Chris Newmarker is the executive editor of WTWH Media life science's news websites and publications including MassDevice, Medical Design & Outsourcing and more. A professional journalist of 18 years, he is a veteran of UBM (now Informa) and The Associated Press whose career has taken him from Ohio to Virginia, New Jersey and, most recently, Minnesota. He’s covered a wide variety of subjects, but his focus over the past decade has been business and technology. He holds bachelor’s degrees in journalism and political science from Ohio State University. Connect with him on LinkedIn or email at cnewmarker@wtwhmedia.com.